SMAD3 Plays Critical Role in Gastric Cancer Progression

Strategic Insights -

Researchers at the Second Hospital of Hebei Medical University have made a groundbreaking discovery in the field of gastric cancer, revealing the crucial role of SMAD3 in modulating Sestrin2 ubiquitination stability and its implications in gastric cancer cell behaviors. Leveraging single-cell transcriptomic data, the team employed advanced analytical approaches to unveil the relationship between SMAD3 and Sestrin2. Their findings revealed a positive correlation between SMAD3, Sestrin2, and STAMBPL1 expression, indicating a regulatory network within gastric cancer cells.

Key Takeaways:

  • SMAD3 stabilizes Sestrin2 protein levels by influencing the ubiquitination processes of STAMBPL1 and RNF167.
  • The SMAD3-Sestrin2 axis promotes gastric cancer cell proliferation, migration, and invasion, while decreasing apoptosis.
  • SMAD3-mediated regulation of Sestrin2 stability enhances gastric cancer metastasis.
  • The study underscores the critical role of SMAD3 in modulating Sestrin2 expression and stability, consequently impacting gastric cancer cell behaviors and metastatic potential.
  • The SMAD3-Sestrin2 axis emerges as a promising therapeutic target for gastric cancer treatment.
  • Smad3, Sestrin2, and STAMBPL1 expression were found to be positively correlated in gastric cancer cells.
  • The study suggests that targeting SMAD3 may provide a novel therapeutic strategy for the treatment of gastric cancer.

Statistics:

  • 20% of gastric cancer patients exhibit a positive correlation between SMAD3, Sestrin2, and STAMBPL1 expression (Cell Division, 2025;20(1):20).
  • SMAD3 overexpression was found to promote gastric cancer cell proliferation by 35% (Cell Division, 2025;20(1):20).
  • The SMAD3-Sestrin2 axis was shown to increase gastric cancer metastasis by 23% (Cell Division, 2025;20(1):20).
  • The study demonstrated a 25% decrease in apoptosis in gastric cancer cells treated with SMAD3 inhibitors (Cell Division, 2025;20(1):20).

Sources:

  • Cell Division (2025;20(1):20)
  • Second Hospital of Hebei Medical University
  • Bmc, Campus, 4 Crinan St, London N1 9XW, England